Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
102.49
+1.58 (1.57%)
At close: May 30, 2025, 4:00 PM
102.19
-0.30 (-0.29%)
After-hours: May 30, 2025, 4:00 PM EDT
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for Ligand Pharmaceuticals stock ranges from a low of $135 to a high of $160. The average analyst price target of $144.71 forecasts a 41.19% increase in the stock price over the next year.
Price Target: $144.71 (+41.19%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $142 → $145 | Buy | Maintains | $142 → $145 | +41.48% | May 9, 2025 |
| Stifel | Stifel | Strong Buy Initiates $143 | Strong Buy | Initiates | $143 | +39.53% | Apr 10, 2025 |
| Benchmark | Benchmark | Strong Buy Reiterates $135 | Strong Buy | Reiterates | $135 | +31.72% | Dec 23, 2024 |
| Barclays | Barclays | Buy Maintains $150 → $160 | Buy | Maintains | $150 → $160 | +56.11% | Dec 16, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $141 → $143 | Buy | Maintains | $141 → $143 | +39.53% | Dec 11, 2024 |
Financial Forecast
Revenue This Year
196.68M
from 167.13M
Increased by 17.68%
Revenue Next Year
233.43M
from 196.68M
Increased by 18.69%
EPS This Year
6.23
from -0.22
EPS Next Year
6.70
from 6.23
Increased by 7.51%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 209.8M | 255.3M | 321.2M | ||
| Avg | 196.7M | 233.4M | 276.0M | ||
| Low | 181.4M | 208.8M | 240.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 25.5% | 29.8% | 37.6% | ||
| Avg | 17.7% | 18.7% | 18.2% | ||
| Low | 8.6% | 6.2% | 3.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.53 | 7.74 | 9.09 | ||
| Avg | 6.23 | 6.70 | 8.21 | ||
| Low | 5.88 | 4.38 | 7.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 24.2% | 35.8% | ||
| Avg | - | 7.5% | 22.6% | ||
| Low | - | -29.7% | 12.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.